Targeted delivery of drugs for liver fibrosis

Expert Opinion on Drug Delivery

Volumn 6, Issue 5, 2009, Pages 531-541

  Li, Feng ^b   Wang, Ji Yao ^a,b  

^a FUDAN UNIVERSITY   (China)

^b Beijing Military Region of Chinese   (China)

Author keywords

Antifibrosis; Delivery systems; Hepatic stellate cells; Liver fibrosis; Target

Indexed keywords

ALPHA1 INTERFERON; ALPHA1B INTERFERON; ANTIFIBROTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; BOVINE SERUM ALBUMIN; DILINOLEOYLPHOSPHATIDYLCHOLINE; DOXORUBICIN; GLIOTOXIN; GLYCYRRHETINIC ACID; HUMAN MONOCLONAL ANTIBODY; HUMAN SERUM ALBUMIN; LIPOSOME; LOSARTAN; MANNOSE 6 PHOSPHATE; MONENSIN; PENTOXIFYLLINE; PHOSPHATIDYLCHOLINE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROSTAGLANDIN J2; RETINOL; RETINOL BINDING PROTEIN; SCATTER FACTOR; SMALL INTERFERING RNA; SYNAPTOPHYSIN; UNCLASSIFIED DRUG;

ADENO ASSOCIATED VIRUS; COMPLEX FORMATION; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG RECEPTOR BINDING; DRUG TARGETING; ENDOTHELIUM CELL; FIBROGENESIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KUPFFER CELL; LIVER CELL; LIVER FIBROSIS; NONHUMAN; REVIEW; STELLATE CELL; TARGET CELL; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT;

ANIMALS; ANTIBODIES, MONOCLONAL; DEPENDOVIRUS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; ENDOTHELIAL CELLS; GENE THERAPY; HEPATIC STELLATE CELLS; HUMANS; KUPFFER CELLS; LIVER CIRRHOSIS; MANNOSEPHOSPHATES; PEPTIDES, CYCLIC; RECEPTORS, CELL SURFACE; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SERUM ALBUMIN; SYNAPTOPHYSIN;

EID: 67649114586     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425240902936834     Document Type: Review

References (99)

1. Day CP. Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut 2002;50:585-588
2. Iredale JP. Cirrhosis: new research provides a basis for rational and targeted treatments. BMJ 2003;327:143-147
3. Friedman SL. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med 1993;328:1828-1835
4. Fallowfield JA, Iredale JP. Reversal of liver fibrosis and cirrhosis - an emerging reality. Scott Med J 2004;49:3-6 (Pubitemid 38325268)
5. Beljaars L, Molema G, Weert B, et al. Albumin modified with mannose 6-Phosphate: a potential carrier for selective delivery of antifibrotic drugs to rat and human hepatic stellate cells. Hepatology 1999;29:1486-1493 (Pubitemid 29211051)
6. Friedman SL. Liver fibrosis - from bench to bedside. J Hepatol 2003;38:S38-53 (Pubitemid 36286562)
7. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:209-218 (Pubitemid 40385459)
8. Maher JJ. Interactions between hepatic stellate cells and the immune system. Semin Liver Dis 2001;21:417-426 (Pubitemid 32923769)
9. Pinzani M, Marra F. Cytokine receptors and signaling in hepatic stellate cells. Semin Liver Dis 2001;21:397-416 (Pubitemid 32923768)
10. Reynaert H, Thompson MG, Thomas T, Geerts A. Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension. Gut 2002;50:571-581 (Pubitemid 34638880)
11. Pinzani M, Rombouts K, Colagrande S. Fibrosis in chronic liver diseases: diagnosis and management. J Hepatol 2005;42:S22-36 (Pubitemid 40364601)
12. Beljaars L, Poelstra K, Molema G, Meijer DKF. Targeting sugar- and charge-modified albumins to fibrotic rat livers: the accessibility of hepatic cells after chronic bile duct ligation. J Hepatol 1998;29:579-588 (Pubitemid 28484947)
13. Torchilin VP. Drug targeting. Eur J Pharm Sci 2000;11:S81-91 (Pubitemid 30734420)
14. Beljaars L, Meijer DK, Poelstra K. Targeting hepatic stellate cells for cell-specific treatment of liver fibrosis. Front Biosci 2002;7:e214-22
15. Elrick LJ, Leel V, Blaylock MG, et al. Generation of a monoclonal human single chain antibody fragment to hepatic stellate cells - a potential mechanism for targeting liver anti-fibrotic therapeutics. J Hepatol 2005;42:888-896 (Pubitemid 40693206)
16. Beljaars L, Molema G, Schuppan D, et al. Successful targeting to rat hepatic stellate cells using albumin modified with cyclic peptides that recognize the collagen type VI receptor. J Biol Chem 2000;275:12743-12751 (Pubitemid 30241427)
17. Aina OH, Marik J, Liu R, et al. Identification of novel targeting peptides for human ovarian cancer cells using 'one-bead one-compound' combinatorial libraries. Mol Cancer Ther 2005;4:806-813
18. De Bleser PJ, Scott CD, Niki T, et al. Insulin-like growth factor II/mannose 6-phosphate-receptor expression in liver and serum during acute CCl4 intoxication in the rat. Hepatology 1996;23:1530-1537 (Pubitemid 26181237)
19. Scharf JG, Knittel T, Dombrowski F, et al. Characterization of the IGF axis components in isolated rat hepatic stellate cells. Hepatology 1998;27:1275-1284 (Pubitemid 28227854)
20. Kornfeld S. Structure and function of the mannose 6-phosphate/insulinlike growth factor II receptors. Annu Rev Biochem 1992;61:307-330
21. Beljaars L, Olinga P, Molema G, et al. Characteristics of the hepatic stellate cell-selective carrier mannose 6-phosphate modified albumin (M6P28-HSA). Liver 2001;21:320-328 (Pubitemid 32910556)
22. Schneiderhan W, Schmid-Kotsas A, Zhao J, et al. Oxidized low-density lipoproteins bind to the scavenger receptor, CD36, of hepatic stellate cells and stimulate extracellular matrix synthesis. Hepatology 2001;34:729-737 (Pubitemid 32927997)
23. Adrian JE, Poelstra K, Scherphof GL, et al. Interaction of targeted liposomes with primary cultured hepatic stellate cells: involvement of multiple receptor systems. J Hepatol 2006;44:560-567 (Pubitemid 43227881)
24. Kamps JA, Morselt HW, Swart PJ, et al. Massive targeting of liposomes, surface-modified with anionized albumins, to hepatic endothelial cells. Proc Natl Acad Sci USA 1997;94:11681-11685 (Pubitemid 27451058)
25. Dahms NM, Hancock MK. P-type lectins. Biochim Biophys Acta 2002;1572:317-340 (Pubitemid 35246353)
26. Hughes DA, Fraser IP, Gordon S. Murine macrophage scavenger receptor: in vivo expression and function as receptor for macrophage adhesion in lymphoid and non-lymphoid organs. Eur J Immunol 1995;25:466-473
27. Pitas RE, Friera A, McGuire J, Dejager S. Further characterization of the acetyl LDL (scavenger) receptor expressed by rabbit smooth muscle cells and fibroblasts. Arterioscler Thromb 1992;12:1235-1244
28. Schuppan D, Strobel D, Hahn EG. Hepatic fibrosis - therapeutic strategies. Digestion 1998;59:385-390 (Pubitemid 28360698)
29. Mukherjee S, Ghosh RN, Maxfield FR. Endocytosis. Physiol Rev 1997;77:759-803
30. Luk JM, Zhang QS, Lee NP, et al. Hepatic stellate cell-targeted delivery of M6P-HSA-glycyrrhetinic acid attenuates hepatic fibrogenesis in a bile duct ligation rat model. Liver Intern 2007;27:548-557 (Pubitemid 46534577)
31. Hagens WI, Beljaars L, Mann DA, et al. Cellular targeting of the apoptosis-inducing compound gliotoxin to fibrotic rat livers. J Pharmacol Exp Ther 2008;324:902-910
32. Gonzalo T, Talman EG, Van de Ven A, et al. Selective targeting of pentoxifylline to hepatic stellate cells using a novel platinum-based linker technology. J Control Release 2006;111:193-203 (Pubitemid 43290008)
33. Gonzalo T, Bataller R, Sancho-Bru P, et al. Short-term treatment with losartan targeted to activated stellate cells reduces advanced liver fibrogenesis: a new strategy to treat liver fibrosis. Hepatology 2005;42:604A
34. Greupink R, Bakker HI, Bouma W, et al. The antiproliferative drug doxorubicin inhibits liver fibrosis in bile duct-ligated rats and can be selectively delivered to hepatic stellate cells in vivo. J Pharmacol Exp Ther 2006;317:514-521
35. Ueki T, Kaneda Y, Tsutsui H, et al. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med 1999;5:226-230 (Pubitemid 29068532)
36. Isaka Y, Tsujie M, Ando Y, et al. Transforming growth factor-beta 1 antisense oligodeoxynucleotides block interstitial fibrosis in unilateral ureteral obstruction. Kidney Int 2000;58:1885-1892 (Pubitemid 30807916)
37. Adrian JE, Kamps JA, Poelstra K, et al. Delivery of viral vectors to hepatic stellate cells in fibrotic livers using HVJ envelopes fused with targeted liposomes. J Drug Target 2007;15:75-82 (Pubitemid 47161334)
38. Adrian JE, Poelstra K, Scherphof GL, et al. Effects of a new bioactive lipid-based drug carrier on cultured hepatic stellate cells and liver fibrosis in bile duct-ligated rats. J Pharmacol Exp Ther 2007;321:536-543 (Pubitemid 46624503)
39. Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol 1996;12:697-715 (Pubitemid 26422728)
40. Aumailley M, Gayraud B. Structure and biological activity of the extracellular matrix. J Mol Med 1998;76:253-265 (Pubitemid 28098711)
41. Loreal O, Clement B, Schuppan D, et al. Distribution and cellular origin of collagen VI during development and in cirrhosis. Gastroenterology 1992;102:980-987
42. Takahara T, Sollberg S, Muona P, Uitto J. Type VI collagen gene expression in experimental liver fibrosis: quantitation and spatial distribution of mRNAs, and immunodetection of the protein. Liver 1995;15:78-86
43. Marcelino J, McDevitt CA. Attachment of articular cartilage chondrocytes to the tissue form of type VI collagen. Biochim Biophys Acta 1995;1249:180-188
44. Meijer DKF, Beljaars L, Molema G, Poelstra K. Disease-induced drug targeting using novel peptide-ligand albumins. J Control Release 2001;72:157-164 (Pubitemid 32522353)
45. Du SL, Pan H, Lu WY, et al. Cyclic Arg-Gly-Asp peptide labeled liposomes for targeting drug therapy of hepatic fibrosis in rats. J Pharmacol Exp Ther 2007;322:560-568
46. Li F, Sun JY, Wang JY, et al. Effect of hepatocyte growth factor encapsulated in targeted liposomes on liver cirrhosis. J Control Release 2008;131:77-82
47. Edelmann L, Hanson PI, Chapman ER, Jahn R. Synaptobrevin binding to synaptophysin: a potential mechanism for controlling the exocytotic fusion machine. EMBO J 1995;14:224-231
48. Kalina M, Lukinius A, Grimelius L, et al. Ultrastructural localization of synaptophysin to the secretory granules of normal glucagon and insulin cells in human islets of Langerhans. Ultrastruct Pathol 1991;15:215-219
49. Gould VE, Lee I, Warren WH. Immunohistochemical evaluation of neuroendocrine cells and neoplasms of the lung. Pathol Res Pract 1988;183:200-213 (Pubitemid 18119322)
50. Oberg K. Neuroendocrine gastrointestinal tumours. Ann Oncol 1996;7:453-463 (Pubitemid 26232950)
51. Poola I, Graziano SL. Expression of neuron-specific enolase, chromogranin A, synaptophysin and Leu-7 in lung cancer cell lines. J Exp Clin Cancer Res 1998;17:165-173 (Pubitemid 28335575)
52. Evans GJ. Tyrosine phosphorylation of synaptophysin in synaptic vesicle recycling. Biochem Soc Trans 2005;33:1350-1353 (Pubitemid 41779685)
53. Cassiman D, van Pelt J, De Vos R, et al. Synaptophysin: a novel marker for human and rat hepatic stellate cells. Am J Pathol 1999;155:1831-1839
54. Elrick LJ, Leel V, Blaylock MG, et al. Generation of a monoclonal human single chain antibody fragment to hepatic stellate cells - a potential mechanism for targeting liver anti-fibrotic therapeutics. J Hepatol 2005;42:888-896 (Pubitemid 40693206)
55. Douglass A, Wallace K, Parr R, et al. Antibody-targeted myofibroblast apoptosis reduces fibrosis during sustained liver injury. J Hepatol 2008;49:88-98
56. Powell DW, Mifflin RC, Valentich JD, et al. Myofibroblasts. I. Paracrine cells important in health and disease. Am J Physiol 1999;277:C1-9
57. Heldin CH. Simultaneous induction of stimulatory and inhibitory signals by PDGF. FEBS Lett 1997;410:17-21 (Pubitemid 27283375)
58. Claesson-Welsh L. Signal transduction by the PDGF receptors. Prog Growth Factor Res 1994;5:37-54 (Pubitemid 2047538)
59. Friedman SL. The virtuosity of hepatic stellate cells. Gastroenterology 1999;117:1244-1246 (Pubitemid 29512687)
60. Win KM, Charlotte F, Mallat A, et al. Mitogenic effect of transforming growth factor-beta 1 on human Ito cells in culture - evidence for mediation by endogenous platelet-derived growth factor. Hepatology 1993;18:137-145 (Pubitemid 23193628)
61. Wong L, Yamasaki G, Johnson RJ, Friedman SL. Induction of β platelet-derived growth factor receptor in rat hepatic lipocytes during cellular activation in vivo and in culture. J Clin Invest 1994;94:1563-1569 (Pubitemid 2138802)
62. Pinzani M, Milani S, Herbst H, et al. Expression of platelet-derived growth factor and its receptors in normal human liver and during active hepatic fibrogenesis. Am J Pathol 1996;148:785-800 (Pubitemid 126660671)
63. Clements JM, Bawden LJ, Bloxidge RE, et al. Two PDGF-B chain residues, arginine 27 and isoleucine 30, mediate receptor binding and activation. EMBO J 1991;10:4113-4120 (Pubitemid 21905442)
64. Beljaars L, Weert B, Geerts A, et al. The preferential homing of a platelet derived growth factor receptor-recognizing macromolecule to fibroblast-like cells in fibrotic tissue. Biochem Pharmacol 2003;66:1307-1317 (Pubitemid 37130306)
65. Fretto LJ, Snape AJ, Tominson JE, et al. Mechanism of platelet-derived growth factor (PDGF) AA, AB, and BB binding to alpha and beta receptor. J Biol Chem 1993;268:3625-3631 (Pubitemid 23071006)
66. Li L, Tao J, Davaille J, et al. 15-deoxy-Delta 12,14-prostaglandin J2 induces apoptosis of human hepatic myofibroblasts. A pathway involving oxidative stress independently of peroxisome-proliferator- activated receptors. J Biol Chem 2001;276:38152-38158 (Pubitemid 37384069)
67. Li L, Grenard P, Nhieu JT, et al. Heme oxygenase-1 is an antifibrogenic protein in human hepatic myofibroblasts. Gastroenterology 2003;125:460-469 (Pubitemid 36929428)
68. Miyahara T, Schrum L, Rippe R, et al. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem 2000;275:35715-35722 (Pubitemid 30841104)
69. Cawello W, Schweer H, Muller R, et al. Metabolism and pharmacokinetics of prostaglandin E(1) administered by intravenous-infusion in human subjects. Eur J Clin Pharmacol 1994;46:275-277
70. Hagens WI, Mattos A, Greupink R, et al. Targeting 15d-prostaglandin J2 to hepatic stellate cells: two options evaluated. Pharm Res 2007;24:566-574 (Pubitemid 46295161)
71. Blomhoff R, Wake K. Perisinusoidal stellate cells of the liver: important roles in retinol metabolism and fibrosis. FASEB J 1991;5:271-277 (Pubitemid 21892886)
72. Fortuna VA, Martucci RB, Trugo LC, Borojevic R. Hepatic stellate cells uptake of retinol associated with retinol-binding protein or with bovine serum albumin. J Cell Biochem 2003;90:792-805 (Pubitemid 37392469)
73. Sato Y, Murase K, Kato J, et al. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat biotechnol 2008;26:431-442 •• This article was designed with a businesslike procedure to demonstrate the targeted effect of vitamin A-coupled liposomes in fibrotic liver, which may be considered as a typical article.
74. Sauk JJ, Smith T, Norris K, Ferreira L. Hsp47 and the translation-translocation machinery cooperate in the production of alpha 1(I) chains of type I procollagen. J Biol Chem 1994;269:3941-3946
75. Nagata K. Expression and function of heat shock protein 47: a collagen-specific molecular chaperone in the endoplasmic reticulum. Matrix Biol 1998;16:379-386 (Pubitemid 28069864)
76. Rockey DC. The cell and molecular biology of hepatic fibrogenesis: clinical and therapeutic implications. Clin Liver Dis 2000;4:319-355 (Pubitemid 30460827)
77. Fujimoto J, Kaneda Y. Reversing liver cirrhosis: impact of gene therapy for liver cirrhosis. Gene Ther 1999;6:305-306 (Pubitemid 29132331)
78. Monahan PE, Salmuski RJ. AAV vectors: is clinical success on the horizon? Gene Ther 2000;7:24-30
79. Summerford C, Samulski RJ. Membrane-associated heparin sulfate proteoglycan is a receptor for adeno-associated virus type 2 virons. J Virol 1998;72:1438-1445 (Pubitemid 28116931)
80. Summerford C, Bartlett J, Samulski RJ. αVβ5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat Med 1999;5:78-82 (Pubitemid 29051002)
81. Qing K, Mah C, Hansen J, et al. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adenoassociated virus 2. Nat Med 1999;5:71-77 (Pubitemid 29051001)
82. Tsui TY, Lau CK, Ma J, et al. rAAV-mediated stable expression of heme oxygenase-1 in stellate cells: a new approach to attenuate liver fibrosis in rats. Hepatology 2005;42:335-342 (Pubitemid 41061086)
83. Bioulac-Sage P, Kuiper J, Van Berkel TJ, Balabaud C. Lymphocyte and macrophage populations in the liver. Hepatogastroenterology 1996;43:4-14 (Pubitemid 26083761)
84. Adams DH. Lymphocyte-endothelial cell interactions in hepatic inflammation. Hepatogastroenterology 1996;43:32-43 (Pubitemid 26083763)
85. Bijsterbosch MK, Manoharan M, Rump ET, et al. In vivo fate of phosphorothioate antisense oligodeoxynucleotides: predominant uptake by scavenger receptors on endothelial liver cells. Nucleic Acids Res 1997;25:3290-3296
86. Schnitzer JE, Bravo J. High affinity binding, endocytosis, and degradation of informationally modified albumins. Potential role of gp30 and gp18 as novel scavenger receptors. J Biol Chem 1993;268:7562-7570 (Pubitemid 23105658)
87. Yoshioka T, Yamamoto K, Kobashi H, et al. Receptor-mediated endocytosis of chemically modified albumins by sinusoidal endothelial cells and Kupffer cells in rat and human liver. Liver 1994;14:129-137 (Pubitemid 24221768)
88. De Rijke YB, Biessen EA, Vogelezang CJ, Van Berkel TJ. Binding characteristics of scavenger receptors on liver endothelial and Kupffer cells for modified low-density lipoproteins. Biochem J 1994;304:69-73 (Pubitemid 24354226)
89. Melgert BN, Wartna E, Lebbe C, et al. Targeting of naproxen covalently linked to HSA to sinusoidal cell types of the liver. J Drug Target 1998;5:329-342 (Pubitemid 28451321)
90. Kamps JA, Morselt HW, Swart PJ, et al. Massive targeting of liposomes, surface-modified with anionized albumins, to hepatic endothelial cells. Proc Natl Acad Sci USA 1997;94:11681-11685 (Pubitemid 27451058)
91. Jansen RW, Olinga P, Harms G, Meijer DK. Pharmacokinetic analysis and cellular distribution of the anti-HIV compound succinylated human serum albumin (Suc-HSA) in vivo and in the isolated perfused rat liver. Pharm Res 1993;10:1611-1614 (Pubitemid 23325664)
92. Franssen EJ, Jansen RW, Vaalburg M, Meijer DK. Hepatic and intrahepatic targeting of an anti-inflammatory agent with human serum albumin and neoglycoproteins as carrier molecules. Biochem Pharmacol 1993;45:1215-1226 (Pubitemid 23098318)
93. Jansen RW, Molema G, Ching TL, et al. Hepatic endocytosis of various types of mannose-terminated albumins. What is important, sugar recognition, net charge or the combination of these features. J Biol Chem 1991;266:3343-3348 (Pubitemid 21909214)
94. Beljaars L, Poelstra K, Molema G, Meijer DK. Targeting sugar- and charge-modified albumins to fibrotic rat livers: the accessibility of hepatic cells after chronic bile duct ligation. J Hepatol 1998;29:579-588 (Pubitemid 28484947)
95. Melgert BN, Olinga P, Jack VK, et al. Dexamethasone coupled to albumin is selectively taken up by rat nonparenchymal liver cells and attenuates LPS-induced activation of hepatic cells. J Hepatol 2000;32:603-611 (Pubitemid 30180380)
96. Melgert BN, Weert B, Schellekens H, et al. The pharmacokinetic and biological activity profile of dexamethasone targeted to sinusoidal endothelial and kupffer cells. J Drug Target 2003;11:1-10 (Pubitemid 36527390)
97. Duffield JS, Forbes SJ, Constandinou CM, et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 2005;115:56-65 (Pubitemid 40385505)
98. Friedman SL. Targeting siRNA to arrear fibrosis. Nat Biotechnol 2008;26:399-440
99. Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343-350 (Pubitemid 40439195)